Seroquel

AstraZeneca PLC
09 November 2005



ASTRAZENECA COMMENCES PATENT INFRINGEMENT LITIGATION AGAINST TEVA


AstraZeneca announced today that it has filed a lawsuit in the United States
District Court for the District of New Jersey against Teva Pharmaceuticals USA,
Inc. and Teva Pharmaceuticals Industries, Ltd. for willful infringement of
AstraZeneca's substance patent protecting Seroquel.



The lawsuit is in response to an Abbreviated New Drug Application filed by Teva
with the US Food and Drug Administration regarding Teva's intent to market a
generic version of AstraZeneca's Seroquel (quetiapine fumarate) in the US prior
to the expiration of AstraZeneca's Patent No. 4,879,288, which is listed in the
FDA's Orange Book and which expires in 2011, subject to any extension.



AstraZeneca has full confidence in and will continue vigorously to defend and
enforce its intellectual property rights protecting Seroquel.



9 November 2005


Media Enquiries:


Edel McCaffrey, Tel: [phone]
Steve Brown, Tel: [phone]

Investor Enquiries:

Mina Blair, Tel: [phone]
Jonathan Hunt, Tel:  [phone]
Ed Seage, Tel: [phone]
Jorgen Winroth, Tel + 1 212 579 0506



-Ends-


                      This information is provided by RNS
            The company news service from the London Stock Exchange